RollingStone Co

RollingStone Co EBIT Margin

The EBIT Margin (Operating Margin) of RollingStone Co (214610.KQ) as of Oct 22, 2026 is -91.27 %. In the previous year, EBIT Margin (Operating Margin) was -445.08 % — a change of -79.49% (higher).

EBIT Margin

-91.27 %

YoY

-79.49%

Last updated:

EBIT Margin (Operating Margin) of RollingStone Co is 2025 -91.27 % . EBIT Margin (Operating Margin) of RollingStone Co was 2024 -445.08 % . It decreases by -79.49% higher compared to the previous year.

RollingStone Co's operating (EBIT) margin stands at -91.3%, down from -36.0% several years earlier.

The RollingStone Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-237.63 KRW
Jan 1, 2019
-334.66 KRW
Jan 1, 2020
7.51 KRW
Jan 1, 2021
-35.95 KRW
Jan 1, 2022
-167.45 KRW
Jan 1, 2023
-379.28 KRW
Jan 1, 2024
-445.08 KRW
Jan 1, 2025
-91.27 KRW
The RollingStone Co EBIT Margin history
YEAREBIT MarginYoY
-91.27 %-79.49%
-445.08 %+17.35%
-379.28 %+126.50%
-167.45 %+365.72%
-35.95 %-579.02%
7.51 %-102.24%
-334.66 %+40.83%
-237.63 %-43.63%
-421.58 %+32.91%
-317.19 %+88.66%
-168.13 %-29.30%
-237.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RollingStone Co Stock analysis

What does RollingStone Co do? MiCo BioMed Co. Ltd. generates revenue through three business segments. The Molecular Diagnosis segment sells nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. The Biochemical Diagnosis segment supplies complex diagnostics, anemia meters, blood glucose meters, medical devices, and strips. The Immunodiagnostic Business segment produces and sells immunodiagnostic devices and immunodiagnostic kits. These products are sold to healthcare providers and medical facilities that require diagnostic tools for patient testing and analysis. The company's products target healthcare institutions including hospitals and clinics. Medical professionals use these devices for accurate diagnosis and treatment planning. The Biochemical Diagnosis segment's blood glucose meters and anemia meters are particularly used in point-of-care testing environments. The Molecular Diagnosis segment's gene amplification equipment supports laboratory-based genetic testing procedures. MiCo BioMed's business model focuses on direct sales to medical institutions and healthcare providers. The company does not mention any third-party distributors or online sales channels. Its product portfolio serves both hospital laboratories and outpatient diagnostic centers. The Immunodiagnostic Business segment's kits are designed for rapid testing applications in clinical settings. RollingStone Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RollingStone Co stock

EBIT Margin (Operating Margin) of RollingStone Co is -91.27 % in 2025.

EBIT Margin (Operating Margin) of RollingStone Co changed from -445.08 % to -91.27 %, representing a -79.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) RollingStone Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s RollingStone Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — RollingStone Co

All Key Metrics — RollingStone Co